Literature DB >> 25944378

Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study.

Anat Gafter-Gvili1,2, Elena Ribakovsky2,3, Nadav Mizrahi2, Abraham Avigdor2,3, Ariel Aviv4, Liat Vidal1,2, Ron Ram2,5, Chava Perry5, Irit Avivi2,5, Meirav Kedmi2,3, Arnon Nagler2,3, Pia Raanani1,2, Ronit Gurion1,2.   

Abstract

A multi-center retrospective analysis of a cohort of patients in Israel treated with any bendamustine containing regimen between 2010-2014 was performed in order to determine the incidence and predictors for infection. The Kaplan Meier Model, employing log rank analysis, was used to assess time-to-infection. The Cox Proportional Hazards model was used to analyze multivariate effects of risk and 234 patients were included in the analysis. One hundred and nine (46.6%) developed at least one infection and 33.76% had severe infections. Seventy-six (41.5%) developed bacterial infection, nine (3.8%) fungal infection and 26 (11.5%) had viral infections. Factors significantly associated with time to infection on multivariable analysis were: bendamustine-combinations [hazard ratio (HR) = 0.589 (95% CI = 0.374-0.926), p = 0.022], Hb level [HR = 0.791 (95% CI = 0.716-0.875), p < 0.0001] and ischemic heart disease [HR = 1.828 (95% CI = 1.165-2.868), p = 0.009]. Infections were associated with a higher mortality and hospitalization rate.

Entities:  

Keywords:  Bendamustine; infections; lymphoproliferative disorders

Mesh:

Substances:

Year:  2015        PMID: 25944378     DOI: 10.3109/10428194.2015.1046862

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

Review 1.  Idelalisib in the management of lymphoma.

Authors:  Chan Yoon Cheah; Nathan H Fowler
Journal:  Blood       Date:  2016-06-01       Impact factor: 22.113

Review 2.  Waldenstrom's Macroglobulinemia: An Update.

Authors:  Maddalena Mazzucchelli; Anna Maria Frustaci; Marina Deodato; Roberto Cairoli; Alessandra Tedeschi
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

3.  Severe Cytomegalovirus Reactivation in Patient with Low-Grade Non-Hodgkin's Lymphoma after Standard Chemotherapy.

Authors:  Lena Modvig; Ciaran Boyle; Katie Randall; Anton Borg
Journal:  Case Rep Hematol       Date:  2017-10-22

Review 4.  The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.

Authors:  Smita Y Patel; Javier Carbone; Stephen Jolles
Journal:  Front Immunol       Date:  2019-02-08       Impact factor: 7.561

5.  Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma.

Authors:  Pilar Martínez-Barranco; María García-Roa; Roberto Trelles-Martínez; Karmele Arribalzaga; María Velasco; Carlos Guijarro; Javier Marcos; Carolina Campelo; Juan Manuel Acedo-Sanz; Lucía Villalón; Pilar Ricard; María José García-Bueno; Elia Pérez-Fernández; Gil Rodríguez-Caravaca; Francisco-Javier Peñalver
Journal:  Acta Haematol       Date:  2021-11-26       Impact factor: 3.068

6.  Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy.

Authors:  Manabu Suzuki; Daisuke Koyama; Shohei Ikeda; Masumi Sukegawa; Mayumi Teshirogi; Kyohei Misawa; Saburo Tsunoda
Journal:  J Clin Exp Hematop       Date:  2022-03-12

7.  Herpetic esophagitis following bendamustine-containing regimen.

Authors:  Hiromichi Yamane; Yasumasa Monobe; Tomohiro Tanikawa; Nobuaki Ochi; Yoshihiro Honda; Hirofumi Kawamoto; Nagio Takigawa
Journal:  Ther Clin Risk Manag       Date:  2016-06-02       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.